The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Using a combination of urine and plasma biomarkers for the development of a scoring sytem that can diagnose and predict prognosis of prostate cancer.
Maher Albitar
Employment or Leadership Position - NeoGenomics Laboratories
Stock Ownership - NeoGenomics Laboratories
Wanlong Ma
Employment or Leadership Position - NeoGenomics Laboratories
Stock Ownership - NeoGenomics Laboratories
Kevin Diep
Employment or Leadership Position - NeoGenomics Laboratories
Ferras S. Albitar
Employment or Leadership Position - NeoGenomics Laboratories
Herbert A. Fritsche
No relevant relationships to disclose
Neal D. Shore
No relevant relationships to disclose